1. Home
  2. COP vs VRTX Comparison

COP vs VRTX Comparison

Compare COP & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ConocoPhillips

COP

ConocoPhillips

HOLD

Current Price

$114.24

Market Cap

126.7B

Sector

Energy

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$485.34

Market Cap

124.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
COP
VRTX
Founded
1917
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Integrated oil Companies
EDP Services
Sector
Energy
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
126.7B
124.7B
IPO Year
2005
2006

Fundamental Metrics

Financial Performance
Metric
COP
VRTX
Price
$114.24
$485.34
Analyst Decision
Buy
Buy
Analyst Count
23
29
Target Price
$123.65
$539.69
AVG Volume (30 Days)
7.0M
1.6M
Earning Date
04-30-2026
05-04-2026
Dividend Yield
2.62%
N/A
EPS Growth
N/A
836.54
EPS
1.78
4.02
Revenue
$58,944,000,000.00
$2,488,652,000.00
Revenue This Year
$6.88
$10.79
Revenue Next Year
N/A
$10.47
P/E Ratio
$63.30
$121.15
Revenue Growth
7.67
46.20
52 Week Low
$85.59
$362.50
52 Week High
$135.87
$533.67

Technical Indicators

Market Signals
Indicator
COP
VRTX
Relative Strength Index (RSI) 56.73 53.33
Support Level $112.87 $422.12
Resistance Level $122.01 $486.26
Average True Range (ATR) 2.31 15.40
MACD 1.24 -4.02
Stochastic Oscillator 84.60 24.70

Price Performance

Historical Comparison
COP
VRTX

About COP ConocoPhillips

ConocoPhillips is a US-based independent exploration and production firm. Its operations are primarily in Alaska and the Lower 48, with footprints in Canada, Europe, Asia-Pacific, the Middle East, and Africa. It also has substantial integrated LNG production and marketing activities across geographies.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: